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Abstract: Expression quantitative trait loci (eQTL) can provide a link between disease susceptibility 
variants discovered by genetic association studies and biology. To date, eQTL mapping studies have 
been primarily conducted in healthy individuals from population-based cohorts. Genetic effects 
have been known to be context-specific and vary with changing environmental stimuli. We 
conducted a transcriptome- and genome-wide eQTL mapping study in a cohort of patients with 
idiopathic or heritable pulmonary arterial hypertension (PAH) using RNA sequencing (RNAseq) 
data from whole blood. We sought confirmation from three published population-based eQTL 
studies, including the GTEx Project, and followed up potentially novel eQTL not observed in the 
general population. In total, we identified 2314 eQTL of which 90% were cis-acting and 75% were 
confirmed by at least one of the published studies. While we observed a higher GWAS trait 
colocalization rate among confirmed eQTL, colocalisation rate of novel eQTL reported for lung-
related phenotypes was twice as high as that of confirmed eQTL. Functional enrichment analysis of 
genes with novel eQTL in PAH highlighted immune-related processes, a suspected contributor to 
PAH. These potentially novel eQTL specific to or active in PAH could be useful in understanding 
genetic risk factors for other diseases that share common mechanisms with PAH. 
Keywords: expression quantitative trait locus; eQTL; pulmonary arterial hypertension; blood; 
genetics 
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1. Introduction 
The relationship between genomic variability, disease risk and endophenotypes has been a focus 
of many research groups with access to suitable disease cohorts. This has been aided by the increasing 
affordability of genotyping and sequencing methodologies. Interpretation of the mechanisms behind 
the effects of genetic variants discovered to associate with phenotypes poses a challenge as many are 
located in the non-coding space of the genome [1]. Non-coding variants exert no direct effect on 
protein structure, making the biological link to the disease or phenotype more difficult to discern. 
Variants in the non-coding space may instead exert their effect by influencing gene expression [1]. 
Characterising the genomic control of gene expression can offer a handle on understanding the role 
of disease-associated variants by linking them to disrupted pathways [2]. Variants associated with 
the expression of a gene, commonly called expression quantitative trait loci (eQTL), have been 
described, primarily in population-based studies [3–5]. 
Differential gene expression analyses comparing cases and controls may be useful for diagnostic 
and/or prognostic purposes or in identifying genes, which may have a causal role in developing the 
disease [6–8]. In the case of the latter, distinguishing between differentially expressed genes that are 
secondary to the disease and those that contribute to disease development is a significant challenge. 
If the frequency of one or several eQTL for a differentially expressed gene is also different between 
cases and controls, a causal association may be established, given the assumptions of causal inference 
[9] are met. In brief, for a causal relationship to be established between a gene product proxied by an 
eQTL and a disease, the eQTL has to be independent of the confounders of the association between 
the gene and the disease, and it has to have no direct effect on the disease via a pathway that does 
not involve the gene being instrumented. 
Currently, one of the main limiting factors for causal inference analysis using genomic data is 
the number of known eQTL. Certain eQTL effects, which go undetected in healthy cohorts commonly 
used for eQTL mapping, may be unmasked by disease and development. The diagnostic value of 
gene expression profiles, i.e., that they can be used to distinguish affected individuals from non-
affected ones, underlines the uniqueness of the set of genes expressed in a disease state [6,7]. 
Differential gene expression in diverse states (carcinogenesis, inflammation, etc.) or at diverse stages 
(such as stages of embryonic development) becomes evident when comparing the gene correlation 
matrices of a biological system under multiple different conditions. Such techniques are called 
‘differential co-expression networks’ [10] and have been used successfully to identify genes and gene 
sets that are important in the state or stage under investigation in a network of genes [11,12]. By 
principle, functionally involved nodes or modules rewire more frequently than uninvolved ones in 
states they create and/or maintain and, therefore, can be identified [13]. 
With the exception of housekeeping genes, the majority of genes in the human transcriptome 
are tissue-specific. Therefore, tissue selection for gene expression studies of disease is of importance. 
The lung is the most relevant tissue in the pathogenesis of pulmonary arterial hypertension (PAH), a 
disease in which pulmonary vascular remodelling drives right ventricular failure. Whole blood also 
has relevance to PAH and might capture more than just systemic effects given the immune 
component of this disease. The role of inflammation in PAH has been extensively studied, based on 
the observation that inflammatory cells infiltrate the remodeled vascular wall [14]. Since PAH can be 
a complication of many inflammatory diseases, including connective tissue disease, thyroiditis, 
scleroderma, systemic lupus erythematosus, human immunodeficiency virus infection and 
schistosomiasis, it might be reasonable to suspect that inflammatory processes, even in the absence 
of a diagnosed comorbidity, contribute to disease development and maintenance. Another advantage 
of using whole blood instead of lung tissue is the non-invasiveness of sampling and availability. Lung 
samples are often only obtainable from the explanted organ after lung transplantation or from post-
mortem tissues. Appropriate control samples for differential gene expression analyses are equally 
hard to come by. 
This study aimed to characterise the genetic variability of transcriptome-wide gene expression 
in whole blood from 276 consecutively sampled patients with PAH and defined potentially novel 
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eQTL active in this disease state. These potentially disease-specific eQTL could be useful in 
elucidating known genotype-phenotype associations or causal analyses. 
2. Materials and Methods 
2.1. Study Participants and Sample Processing 
A total of 276 patients with idiopathic, heritable or drug-induced PAH diagnosed following 
international guidelines [15] were recruited from expert centres across the UK with whole-genome 
sequence conducted as part of the UK National Institute for Health Research BioResource (NIHRBR) 
study [16,17]. Transcriptome profiling through RNAseq was completed as part of the PAH cohort 
study [18]. Demographic characteristics and white blood cell counts of the individuals in this study 
are shown in Supplementary Table S1. 
2.2. Gene Expression Data 
RNA sequencing and transcript abundance estimation procedures are described in the 
Supplementary Appendix. White blood cell composition was quantified using quanTIseq, a novel 
deconvolution algorithm [19]. Predicted white blood cell fractions from quanTIseq correlated with 
clinical white cell fractions available in a subset of PAH patients (Spearman correlation = 0.44–0.73). 
Well-detected transcripts with a minimum of two reads in at least 95% of samples (n = 26,050) were 
taken forward to the eQTL analyses. 
2.3. Genetic Data 
Whole-genome sequence Hg19-aligned data were available from the NIHRBR study described 
in detail elsewhere [16]. Genetic variants with a minimum minor allele frequency of 5% were 
extracted from the NIHRBR variant call format (VCF) files and further filtered for variants called in 
at least 95% of the samples and had a p-value greater than 10−5 for Hardy Weinberg equilibrium, 
leaving a total of 7,362,566 variants for eQTL mapping. Software tools used in the eQTL mapping 
pipeline included PLINKv1.90 [20] for data extraction and computing multidimensional scaling 
components, QCTOOLv2.0 [21], for variant filtering, and QUICKTESTv1.1 [22] for association 
testing. 
2.4. eQTL Effect Estimation 
Raw gene count data were first variance stabilised to achieve homoskedasticity and then 
quantile normalised to the median distribution. The sample means were then centered to zero, and 
the sample variance was linearly scaled, such that each sample had a standard deviation of one. A 
total of 7,362,566 markers were tested for their effects on the expression of 26,050 well-detected genes. 
Variants within 1 megabase (Mb) on either side of the gene’s transcription start site (TSS) were 
regarded cis-acting or cis-eQTL while all other markers farther on the same chromosome or on 
different chromosomes were regarded trans-eQTL. Each well-detected transcript was modelled as a 
function of genotype (coded 0, 1 or 2 reflecting the number of alternate alleles) in a linear regression 
framework while adjusting for the following covariates: Sex, first four components from 
multidimensional scaling and white blood cell fractions (Supplementary Table S1). The genome-wide 
results were subsequently pruned using the ‘clump’ command in PLINK 1.90 (parameters: --clump-
p1 1.9 × 10−12; --clump-r2 0.01; --clump-kb 1000) to pick the lead variant with the lowest p-value in a 
block of variants in linkage disequilibrium, and thus obtain independent effects. Genetic variants that 
reached the Bonferroni-adjusted significance threshold of 1.9 × 10−12 given by dividing the genome-
wide significance threshold (p ≤ 5 × 10−8) by the number of transcripts tested (n = 26,050) were 
considered eQTL in this study. 
  
Genes 2020, 11, 1247 4 of 13 
 
2.5. Confirmation Rate 
The confirmation rate of eQTL in this study was calculated in the 2 largest published eQTL 
studies to date and the Genotype-Tissue Expression (GTEx) Project [3,4,23] (Table 1) to assess the 
extent to which eQTL in PAH overlapped with eQTL described in healthy populations. These studies 
were selected for having measured gene expression in the same tissue as our study, in addition to 
being the largest eQTL mapping studies to date. No eQTL study other than the GTEx Project with 
available genome-wide results applied RNAseq in whole blood at the time this study was conducted. 
Confirmation rate was defined as the number of PAH eQTL confirmed by the published study, 
divided by the total number of PAH eQTL tested by the published study and multiplied by 100 to 
give a percent value. The matching of gene transcripts and genetic variants between our study and 
the published studies as well as similarities and differences between the designs of this study and the 
3 published studies are described in Table 1 and in the Supplementary Appendix. 
Table 1. Characteristics of the PAH Cohort eQTL mapping study and published eQTL studies used 
for confirmation. 
 Westra et al. Joehanes et al. GTEx This Study 
Gene expression 
array 
Illumina HumanHT-
12 v4.0 
Affymetrix 
HuEx 1.0 ST 
RNAseq RNAseq 
Genotyping panel HapMap2 1000-Genomes WGS WGS 
MAF threshold ≥5% ≥1% ≥1% ≥5% 
n variants in 
analysis 
not reported 8,510,936 10,008,325 7,362,566 
cis-eQTL ≤250 kb from PMP 
≤1 Mb from the 
TSS 
≤1 Mb from 
the TSS 
≤1 Mb from 
the TSS 
trans-eQTL ≥5 Mb from PMP 
>1 Mb from the 
TSS 
>1 Mb from 
the TSS 
>1 Mb from 
the TSS 
Comparison of gene expression- and genetic data and expression quantitative trait locus (eQTL) 
definitions. MAF = minor allele frequency; PMP = probe midpoint; TSS = transcription start site; 
RNAseq = RNA sequencing; WGS = whole-genome sequencing. 
2.6. Overlap with Variants from the GWAS Catalog 
An important aim of this study was to identify eQTL in PAH with effects that had not been 
observed in population-based studies and to assess the relevance of these PAH-specific eQTL to 
related phenotypes and diseases. The NHGRI-EBI GWAS Catalog of published genome-wide 
association studies (GWAS) [24] provided a curated database of genetic markers associated with a 
wide range of traits and diseases. All variant-phenotype pairs below an association p-value threshold 
of 9 × 10−6 were downloaded from the GWAS Catalog website on 5 March 2020. The GWAS Catalog 
at the time contained 113,510 unique variants (including variants in linkage disequilibrium [LD]) 
reported as lead variants for 4314 phenotypes. The list of GWAS variants were intersected with each 
PAH eQTL (including the lead eQTL and variants in LD with the lead eQTL [r2 ≥40%]). The difference 
between the proportions of novel eQTL and previously reported eQTL overlapping lung-related 
phenotypes and diseases curated from the full GWAS Catalog phenotype list was tested using the 2-
sample equality of proportions test. 
2.7. Functional Enrichment Analysis of Genes with Novel eQTL 
Functional enrichment analysis of genes with novel eQTL in PAH using the WEB-based GEne 
SeT AnaLysis Toolkit (WebGestalt) [25] was conducted to determine if genes with novel eQTL were 
predominantly from pathways with relevance to the pathobiology of PAH. A form of pathway 
analysis called over-representation analysis (ORA) [26] was run using the Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathways [27] database to group these genes into a smaller number of 
gene-sets relating to biological processes. We queried the list of genes with novel eQTL whilst all the 
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tested genes also present on the expression array of at least one of the published eQTL studies used 
for the confirmation process constituted the list of background genes. Pathways below a false-
discovery rate (FDR)-corrected significance threshold of 0.05 were considered significant. 
3. Results 
We observed 2354 eQTL in total with the majority (90%) acting in cis (Figure 1A), accounting for 
9% of all genes tested in this transcriptome- and genome-wide eQTL mapping analysis in PAH whole 
blood samples. Of these eQTL, 146 were associated with unmapped transcripts not yet annotated in 
the Ensembl database (Figure 1B). Lead eQTL ranked by the percent of variance explained (R2) in 
gene expression are presented in the Supplementary Table S2. The proportion of variation explained 
(R2) in gene expression levels was generally lower for trans-eQTL than for cis-eQTL (mediancis-eQTL = 
23.1%, IQRcis-eQTL = 12.5%; mediantrans-eQTL = 21.5%, IQRtrans-eQTL = 11.5%; t(df=1332) = 4.5, p-value = 8.3 × 10−6). 
(A) 
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Figure 1. (A) Results of the pulmonary arterial hypertension (PAH) Cohort eQTL mapping. Genomic 
eQTL location (x-axis) plotted against the transcription start site of the gene associated with the eQTL. 
Bubble size and color are proportional to the effect size of the eQTL-gene association. (B) Pie chart 
showing the proportions of cis-, trans- and unmapped eQTL identified in the PAH Cohort eQTL 
mapping. Counts of eQTL within each category are shown next to the category name. An eQTL was 
considered ‘novel’ if it was eligible to be confirmed in at least one of the previously published studies 
and was not reported as an eQTL previously. Those eQTL that reached the study-specific significance 
threshold in at least one of the published studies were considered ‘confirmed’. Unmapped transcripts 
not yet annotated in the Ensembl database could not be confirmed. Ineligible eQTL were not tested 
by any of the three studies used for confirmation. 
3.1. Confirmation Rate 
Out of the 1986 unique genes with cis-eQTL, 1509 (76%) could be mapped to the Illumina HT12v3 
array used by Westra et al. and 2134 (95%) to the Affymetrix Human Exon chip used by Joehanes et 
al., respectively. Results from the GTEx Portal were obtained for 73% of eQTL in this study. Twenty-
eight percent of cis-eQTL were confirmed by Westra et al., 31% by Joehanes et al. and 90% of tested 
cis-eQTL confirmed in GTEx. Overall, 75% of cis-eQTL were confirmed in at least one of the published 
studies (Figure 1). The overall confirmation rate for trans-eQTL reached 16%, with all but one being 
confirmed by GTEx alone. Joehanes et al. confirmed only one trans-eQTL for JAM3 (chr1:248039451 
[C/T]). 
3.2. Overlap with Variants from the GWAS Catalog 
In order to assess the relevance of eQTL identified in this study to a wide range of phenotypes 
and diseases, the 2173 unique eQTL were intersected with the database of published genotype-
phenotype associations from the GWAS Catalog. In total, 929 eQTL were reported for at least one 
trait previously (median N GWAS traits/eQTL = 2; IQR N GWAS traits/eQTL = 3). Ninety-eight (11%) of the 929 eQTL 
had at least 10 or more unique GWAS phenotypes associated with them. Figure 2 shows the number 
of overlapping GWAS phenotypes per eQTL in the confirmed and novel eQTL categories. The 
proportion of cis-acting eQTL overlapping with at least one published GWAS association in the 
confirmed subset was 47%, while in the novel subset, it was 37%. Among trans-eQTL, the proportion 
of loci overlapping at least one GWAS trait was 50% in the confirmed and 27% in the novel group. 
The higher proportion of overlapping loci in the confirmed eQTL groups was significant for both cis- 
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and trans-acting eQTL (two-sample equality of proportions test cis-eQTL: χ2(df=1) = 13.9; 95% CI = 0.05–
0.15; p-value = 0.0002. trans-eQTL: χ2(df=1) = 4.2; 95% CI = −0.003–0.45; p-value = 0.04). Interestingly, the 
proportion of novel eQTL previously reported for lung-related phenotypes (11%) was twice as high 
as the proportion of confirmed eQTL associated with lung-related phenotypes (5.5%) (χ2(df=1) = 6.9; 
95% CI = 0.006–0.1; p-value = 0.009). Lung-related phenotypes reported for the novel eQTL included 
chronic obstructive pulmonary disease (COPD), lung function (forced vital capacity, forced 
expiratory volume), low versus high forced expiratory volume, interstitial lung disease, emphysema, 
lung cancer and lung adenocarcinoma. The full list of 63 QTL overlapping lung-related phenotypes 
in the GWAS Catalog can be found in Supplementary Table S3. 
 
Figure 2. GWAS trait-associations reported for eQTL in the PAH Cohort. Percentage of binned 
numbers of overlapping GWAS traits (y-axis) per eQTL in each eQTL category (x-axis). Reported 
genotype-trait associations were downloaded from the NHGRI-EBI Catalog of published genome-
wide association studies. 
3.3. Functional Enrichment Analysis of Genes with Novel eQTL 
We assessed the list of 606 genes with novel eQTL in the PAH Cohort for their involvement in 
certain biological processes or pathways in the KEGG knowledgebase. Five pathways were found to 
be significantly (FDR <0.05) enriched, with the pathways taste transduction, graft-versus-host disease 
and autoimmune thyroid disease being the three most significant (Table 2). Supplementary Table S4 
lists the overlapping genes driving the association of these five pathways and our results with the 
corresponding eQTL in PAH, including several human leukocyte antigen (HLA) genes. Furthermore, 
all genes overlapping with type I diabetes and allograft rejection pathways come from the HLA class. 
Genes encoded by the more than 200 HLA genes in the highly polymorphic HLA region play an 
important role in antigen processing and presentation. In total, 20 genes with eQTL in this study came 
from the HLA classes I and II (n = 18) and from the HLA class IB (n = 2) genes. Half of these eQTL-
HLA gene associations were found to be novel. Out of the 5 trans- and 17 cis-eQTL, 3 trans- and 8 cis-
eQTL were confirmed by published studies [3,4,23].
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Table 2. Pathways enriched for genes with novel eQTL in the PAH Cohort. 
Gene Set Description Size Overlap Expectation Enrichment Ratio p-Value FDR 
hsa04742 Taste transduction 48 8 0.87 9.24 1.78 × 10−6 5.72 × 10−4 
hsa05332 Graft-versus-host disease 32 6 0.58 10.40 1.85 × 10−5 2.86 × 10−3 
hsa05320 Autoimmune thyroid disease 34 6 0.61 9.79 2.66 × 10−5 2.86 × 10−3 
hsa05330 Allograft rejection 33 5 0.59 8.40 2.75 × 10−4 0.02 
hsa04940 Type I diabetes mellitus 36 5 0.65 7.70 4.19 × 10−4 0.03 
Results of the over-representation analysis using the Kyoto Encyclopedia of Genes and (KEGG) pathway database. Column names: Gene set = searchable identifier 
of the gene set in KEGG; Size = number of genes participating in the gene set and overlap gives the number of genes in the gene set that overlap with the queried 
gene list; Expectation = number of genes that are expected to be shared between the queried gene list and the gene set if the queried list was a random sample of the 
background gene list; Enrichment ratio = fold enrichment of the gene set for the queried gene list; p-value = enrichment significance of the Fisher`s exact test; FDR = 
false discovery rate adjusted significance.
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4. Discussion 
Gene expression serves as an intermediate phenotype between genetic variants and associated 
phenotypes, such as clinical diagnoses, accepted biomarkers and anthropometric and behavioural 
traits. Previous eQTL studies provided support for the idea that genetic effects on gene expression 
have phenotypic consequences and that eQTL aid in the biological interpretation of associated genetic 
markers in disease [3–5]. However, eQTL effects are not only dependent on the tissue or cell type 
under investigation [23,28] but also on the environment or context [5,29–31] in which gene expression 
is measured. This implies that a more comprehensive eQTL map could be constructed by extending 
mapping efforts beyond population-based studies. We ran a transcriptome-wide eQTL analysis in a 
cohort of 276 PAH patients to characterise the genetic control of gene expression variability in this 
condition, uncovering potentially novel eQTL not detected in healthy populations. The resulting 2354 
significant eQTL were intersected with the results of two previously published population-based 
eQTL studies and the results of the GTEx Project. In this study, 25% of cis-eQTL and 84% of trans-
eQTL were not found in any of the three studies used for confirmation. Novel and confirmed eQTL 
were investigated for their relevance to a wide range of diseases, and results focused on lung-related 
phenotypes from the NHGRI-EBI Catalog of published genome-wide association studies (GWAS 
Catalog). 
Nearly half (43%) of all eQTL identified in this study colocalised with at least one trait or disease 
in the GWAS Catalog. Even though the proportion of colocalising eQTL was higher for confirmed 
cis- and trans-eQTL than for novel eQTL, the proportion of eQTL associated with lung-related 
phenotypes was twice as high among novel eQTL than confirmed eQTL previously detected in 
population-based studies. This indicates that these novel eQTL identified in blood samples of PAH 
patients might be highly informative for pulmonary diseases such as COPD, interstitial lung disease 
and emphysema. The higher proportion of GWAS-trait associated eQTL in the confirmed subset 
might be explained by the lack of replication of novel eQTL by an independent PAH cohort; therefore, 
it is expected that a proportion of these novel association signals is spurious. 
As an example for the overlap between lung-related GWAS traits and eQTL in PAH, the novel 
GTF2IRD2B cis-eQTL rs13238996 (Supplementary Table S3) overlaps with multiple phenotypes 
including COPD [32], lung function [33], cardiovascular disease [33] and diastolic blood pressure 
[34]. The Deletion of GTF2IRD2B leads to a rare congenital disease called Williams-Beuren syndrome, 
which frequently presents with supravalvular aortic stenosis (SVAS; OMIM 185500), a congenital 
heart defect characterised by the narrowing of the aorta, pulmonary and coronary arteries and other 
blood vessels [35]. 
Pathway analysis of genes associated with novel eQTL identified five biological processes, 
including four immune-related phenotypes enriched for this list of genes from the KEGG database. 
Six genes from the graft-versus-host disease and allograft rejection pathways overlap with the list of 
genes with novel eQTL, five of which belong to the Human Leukocyte Antigen (HLA) class. The 
immune-related pathways enriched for genes with novel eQTL in this study demonstrate that novel 
eQTL could be identified in disease populations since their gene expression profiles differ from the 
profiles of healthy individuals. The complex pathophysiological mechanisms behind PAH involve 
multiple driving factors of which immune dysfunction and inflammation are suspected to be among 
the major contributors (Rabinovitch et al., 2014). The importance of antigen-presenting and 
recognition in PAH is underlined by the most significant genetic variant discovered in the PAH 
GWAS in the HLA-DPA1/DPB1 locus encoding class II major histocompatibility complex (MHC) 
molecules [16], which associated with three HLA-DPB1 alleles, all containing a glutamic acid at amino 
acid residue 69 (Glu⁶⁹). The HLA-DPA1/DPB1 PAH susceptibility locus emphasises the role of 
immune dysregulation in PAH development [36,37] and warrants further investigation. 
Overall, the confirmation rate of eQTL in this study was comparable to that seen in published 
studies [3,4]. A third of cis-eQTL confirmed in the two population-based studies by Westra et al. and 
Joehanes et al., while 90% of cis-eQTL were confirmed by the GTEx Project. Fifteen percent of trans-
eQTL confirmed in either the GTEx project or the study of Joehanes et al. Trans-eQTL validation rates 
are generally much lower (under 10%) than validation rates of cis-eQTL [3,4], reflecting the higher 
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average effect size of cis-eQTL and a stronger tissue-specificity of trans-eQTL effects compared to cis-
eQTL, which may render trans-eQTL more susceptible to confounding by differing experimental 
conditions and environmental factors. However, the confirmation rate reported by this study and 
other studies possibly underestimate the true extent of eQTL overlap between studies since the list 
of variants and genes that passed quality control and were tested by any one study are usually not 
made available. We observed a higher confirmation rate with the GTEx Project that also used RNAseq 
for assaying gene expression. Similarly, Joehanes et al. reported higher validation rates between two 
array-based studies than between array-based and RNAseq-based studies. This may be related to 
platform differences, for example, hybridisation in arrays is less sensitive than high-depth sequencing 
and potentially affected by differing background signals in various tissues. Differences between the 
study populations being compared can also give rise to imperfect validation and also to novel 
discoveries, as all genetic effects depend on both the genetic (epistasis) and environmental context of 
the population they were estimated in and, therefore, do not necessarily apply to another population 
or the same population at a different time. A more accurate way of identifying novel eQTL in this 
study would have been to contrast PAH eQTL effects with eQTL effects estimated in a control 
population assayed on the same platforms and in one batch with the PAH samples to reduce the 
variability due to technical factors. In addition, novel eQTL are yet to be replicated in an independent 
population of PAH patients to identify true positives. 
The effects of eQTL can vary by the tissue and even cell type under investigation [28,38] and 
may be modified by external and environmental factors [29,30]. Previous studies have successfully 
identified ‘response’ eQTL that are associated with gene expression levels in cells under one of two 
experimental conditions, but not both. For example, in the study of Barreiro, nearly 200 eQTL were 
identified in primary dendritic cells from 65 individuals with effects specific to either the 
Mycobacterium tuberculosis-infected cells or the uninfected ones [29]. These response eQTL were 
argued to constitute natural regulatory variation that likely affect host-Mycobacterium tuberculosis 
interaction and account for interindividual variation in the immune response and susceptibility of 
tuberculosis. The authors of the study found when integrating their data with genome-wide genetic 
susceptibility of pulmonary tuberculosis that these response eQTL were more likely to be associated 
with the disease, uncovering potential susceptibility genes in pulmonary tuberculosis. Another study 
by Fairfax et al. [30] investigated the effect of innate immune stimuli on eQTL effects by exposing 
primary CD14+ cells from 432 European volunteers to the inflammatory cytokine interferon-γ or the 
endotoxin lipopolysaccharide. Inflammatory stimulation revealed hundreds of eQTL specific to 
either stimulus, which were enriched for disease-risk loci. In this study, the proportion of eQTL also 
associated with lung diseases or lung function was twice as high in the novel eQTL subset than in the 
confirmed subset, highlighting the importance of genotype-environment interaction in 
understanding the genetic variation of disease susceptibility characterised by genome-wide 
association studies. 
To date, large-scale eQTL-mapping has been done in healthy individuals from population-based 
studies (Joehanes et al., 2017, Westra et al., 2013, Zhernakova et al., 2017), providing a valuable 
knowledge base for understanding associations between genetic variation and various phenotypes. 
It has been shown that by recapitulating the environmental context relevant to disease, it is possible 
to decipher the genetic variation of disease susceptibility more extensively (Fairfax et al., 2014, 
Barreiro et al., 2012, Çalışkan et al., 2015). Genome- and transcriptome-wide eQTL-mapping in this 
cohort of idiopathic and heritable PAH patients identified hundreds of potentially novel eQTL with 
twice the proportion of lung disease associated with genetic variants than eQTL confirmed by 
population-based studies. Apart from pulmonary conditions, these novel eQTL specific to, or active 
in, PAH could be useful in understanding genetic risk factors for other diseases that share common 
mechanisms with PAH, such as those with immune dysregulation. 
Supplementary Materials: The following are available online at www.mdpi.com/2073-4425/11/11/1247/s1, Table 
S1: Patient characteristics and white blood cell fractions in the PAH Cohort study, Table S2: Lead variants for 
novel eQTL in the PAH Cohort ordered by variance explained in gene expression, Table S3: Phenotypes from 
the NHGRI-EBI GWAS Catalog of published genome-wide association studies reported for novel and confirmed 
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eQTL, Table S4: Significant KEGG pathways from the enrichment analysis of genes with novel eQTL in the PAH 
Cohort. 
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